For research use only. Not for therapeutic Use.
Cefamandole Nafate（Cat No.:I003526）is a second-generation cephalosporin antibiotic, commonly used in clinical settings for its broad-spectrum activity against Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Known for its effectiveness against respiratory, urinary tract, and skin infections, Cefamandole Nafate is often used preoperatively to prevent surgical infections. Its stability and water-soluble formulation allow for effective parenteral administration. Cefamandole Nafate remains relevant in research focused on bacterial resistance and the development of cephalosporin-based therapies.
| Catalog Number | I003526 |
| CAS Number | 42540-40-9 |
| Molecular Formula | C19H17N6NaO6S2 |
| Purity | ≥95% |
| Solubility | DMSO: ≥ 41 mg/mL, H2O: ≥ 29 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | sodium;(6R,7R)-7-[[(2R)-2-formyloxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| InChI | InChI=1S/C19H18N6O6S2.Na/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10;/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30);/q;+1/p-1/t12-,14-,17-;/m1./s1 |
| InChIKey | ICZOIXFFVKYXOM-YCLOEFEOSA-M |
| SMILES | CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)OC=O)SC2)C(=O)[O-].[Na+] |
| Reference | </br>1:Estimation of the two sample preparation techniques for infrared spectroscopic identification of Cefamandole nafate in solid state. Kalinkova GN, Opalchenova G.Pharmeur Sci Notes. 2007 Sep;2007(1):9-13. PMID: 17993089 </br>2:Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi A, Ragunath C, Kaplan JB.Antimicrob Agents Chemother. 2007 Aug;51(8):2733-40. Epub 2007 Jun 4. PMID: 17548491 Free PMC Article</br>3:Kinetics of cefamandole nafate degradation in solid phase. Jelińska A, Zajac M, Gostomska J, Szczepaniak M.Farmaco. 2003 Apr;58(4):309-13. PMID: 12727540 </br>4:Simultaneous determination of cefamandole and cefamandole nafate in human plasma and urine by high-performance liquid chromatography with column switching. Lee HS, Zee OP, Kwon KI.J Chromatogr. 1990 Jun 29;528(2):425-33. PMID: 2384580 </br>5:Prophylaxis with cefamandole nafate in elective orthopedic surgery. Henley MB, Jones RE, Wyatt RW, Hofmann A, Cohen RL.Clin Orthop Relat Res. 1986 Aug;(209):249-54. PMID: 3731606 </br>6:Chemical stabilities of cefamandole nafate and metronidazole when mixed together for intravenous infusion. Das Gupta V, Stewart KR, Dela Torre M.J Clin Hosp Pharm. 1985 Dec;10(4):379-83. PMID: 4093509 </br>7:Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Bosso JA, Townsend RJ.Am J Hosp Pharm. 1985 Oct;42(10):2211-4. PMID: 3864367 </br>8:[Cefamandole nafate in short-term prophylaxis in obstetric and gynecologic surgery]. Accardo FM, Mancuso A, Granese D, Dugo C.Minerva Ginecol. 1983 May;35(5):351-6. Italian. No abstract available. PMID: 6877656 </br>9:Evaluation of cefamandole nafate for the treatment of acute gonococcal salpingitis. Hemsell DL, Cunningham FG, Nobles B.Obstet Gynecol. 1983 May;61(5):635-40. PMID: 6403898 </br>10:Stability of cefamandole nafate injection with parenteral solutions and additives. Frable RA, Klink PR, Engel GL, Mundell EE.Am J Hosp Pharm. 1982 Apr;39(4):622-7. No abstract available. PMID: 7082453 |
